ORLANDO, Fla., May 29, 2009 (GLOBE NEWSWIRE) -- GlaxoSmithKline (NYSE:GSK) and Genmab A/S (Copenhagen:GEN) today announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 that the ARZERRA(TM) (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. Ofatumumab is an investigational treatment.